Purine metabolism gene deregulation in Parkinson's disease

Neuropathology and Applied Neurobiology

Volumn 41, Issue 7, 2015, Pages 926-940

  Garcia Esparcia, Paula ^a,b   Hernández Ortega, Karina ^a   Ansoleaga, Belén ^a   Carmona, Margarita ^a,b   Ferrer, Isidre ^a,b,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Frontal cortex; Parkinson's disease; Purine metabolism enzymes; Putamen; substantia nigra

Indexed keywords

ADENINE PHOSPHORIBOSYLTRANSFERASE; ADENYLATE KINASE 2; ADENYLATE KINASE 3; ADENYLATE KINASE 4; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 3; ENZYME; MESSENGER RNA; NUCLEOSIDE-DIPHOSPHATESE KINASE 7; NUCLEOSIDEDIPHOSPHATESE KINASE 3; PURINE; PURINE NUCLEOSIDE PHOSPHORYLASE 1; UNCLASSIFIED DRUG; PURINE DERIVATIVE;

ARTICLE; BRAIN CORTEX; CELL DEATH; DISEASE COURSE; FRONTAL CORTEX; GENE CONTROL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PURINE METABOLISM; PUTAMEN; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; UPREGULATION; ADULT; AGED; ASTROCYTE; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTES; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROGLIA; MIDDLE AGED; NEURONS; PARKINSON DISEASE; PURINES; PUTAMEN; SUBSTANTIA NIGRA;

EID: 84946496940     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12221     Document Type: Article

References (59)

1. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008; 115: 437-444
2. Dickson DW, Fujishiro H, DelleDonne A, Josephs K, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 3): S1-5
3. Jellinger K. Parkinson's disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Eds DW Dickson, RO Weller . Oxford: Wiley-Blackwell., 2011; 194-223
4. Braak H, del Tredici K, Bratzke H, Hamm-Clement J, Sandemann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl. 3): 1-5
5. Braak H, del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
6. Braak H, Rüb U, Jansen Steur EN, del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic state in Parkinson disease. Neurology 2005; 64: 1404-1410
7. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64: 485-491
8. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415
9. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008; 116: 1-16
10. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25 (Suppl. 1): S78-82
11. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Progr Neurobiol 2009; 88: 89-103
12. Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011; 118: 821-839
13. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010; 30: 1049-1056
14. Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A. Neurochemistry and the non-motor aspects of Parkinson's disease. Neurobiol Dis 2012; 46: 508-526
15. Dunn L, Allen GF, Mamais A, Ling H, Li A, Duberley KE, Hargreaves IP, Pope S, Holton JL, Lees A, Heales SJ, Bandopadhyay R. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol Aging 2014; 35: 1111-1115
16. Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 2008; 8: 2-7
17. Ipata PL, Camici M, Micheli V, Tozzi MG. Metabolic network of nucleosides in the brain. Curr Top Med Chem 2011; 11: 902-922
18. Ansoleaga B, Jove M, Schlüter A, Garcia-Esparcia P, Moreno J, Pujol A, Pamplona R, Portero-Otín M, Ferrer I. Deregulation of purine metabolism in Alzheimer's disease. Neurobiol Aging 2015; 36: 68-80. doi: 10.1016/j.neurobiolaging; pii: S0197-4580(14)00517-X
19. Ribeiro JA, Sebastiao AM, Mendonça A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2003; 68: 377-392
20. Burnstock G, Fredholm BB, Verkhratsky A. Adenosine and ATP receptors in the brain. Curr Top Med Chem 2011; 11: 973-1011
21. Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov Disord 2007; 22: 1990-2017
22. Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004; 127: 1075-1084
23. Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE 2011; 6: e17338
24. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011; 76: 1811-1816
25. Villar-Menéndez I, Porta S, Buira SP, Pereira-Veiga T, Díaz-Sánchez S, Albasanz JL, Ferrer I, Martín M, Barrachina M. Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiol Dis 2014; 69: 206-214
26. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 406-413
27. Vallano A, Fernández-Dueñas V, Pedros C, Arnau JM, Ciruela F. An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol Disord Drug Targets 2011; 10: 659-669
28. Szabó N, Kincses ZT, Vécsei L. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011; 7: 441-455
29. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109
30. Navarro A, Boveris A. Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J Bioenerg Biomembr 2009; 41: 517-521
31. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009; 132: 3285-9327
32. Navarro A, Boveris A, Bández MJ, Sánchez-Pino MJ, Gómez C, Muntané G, Ferrer I. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med 2009; 46: 1574-1580
33. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiol Dis 2005; 18: 492-498
34. Keeney PM, Xie J, Capaldi RA, Bennett JP. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006; 26: 5256-5264
35. Martínez A, Portero-Otin M, Pamplona R, Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010; 20: 281-297
36. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007; 85: 919-934
37. Sanders LH, Greenamyre JT. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med 2013; 62: 111-120
38. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
39. Barrachina M, Castaño E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006; 49: 276-284
40. Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN, Bonnert TP, Ferrer I, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, Grünblatt E, Palkovits M, Parchi P, Capellari S, Arzberger T, Kretzschmar H, Roncaroli F, Dexter DT, Reynolds R. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol 2012; 124: 893-903
41. Rosemeyer H. The chemodiversity of purine as a constituent of natural products. Chem Biodivers 2004; 1: 361-401
42. Dzeja P, Terzic A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci 2009; 10: 1729-1772
43. Noma T. Dynamics of nucleotide metabolism as a supporter of life phenomena. J Med Invest 2005; 52: 127-136
44. Bilitou A, De Marco N, Bello AM, Garzia L, Carotenuto P, Kim M, Campanella C, Ohnuma S, Zollo M. Spatial and temporal expressions of prune reveal a role in Müller gliogenesis during Xenopus retinal development. Gene 2012; 509: 93-103
45. Carotenuto P, Marino N, Bello AM, D'Angelo A, Di Porzio U, Lombardi D, Zollo M. PRUNE and NM23-M1 expression in embryonic and adult mouse brain. J Bioenerg Biomembr 2006; 38: 233-246
46. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signaling cascade. Biochim Biophys Acta 2008; 1783: 673-694
47. Kaczmarek E, Koziak K, Sévigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271: 33116-33122
48. Kegel B, Braun N, Heine P, Maliszewski CR, Zimmermann H. An ecto-ATPase and an ecto-ATP diphosphohydrolase are expressed in rat brain. Neuropharmacology 1997; 36: 1189-1200
49. Wink MR, Braganhol E, Tamajusuku AS, Lenz G, Zerbini LF, Libermann TA, Sévigny J, Battastini AM, Robson SC. Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 2006; 138: 421-432
50. Inouye S, Seo M, Yamada Y, Nakazawa A. Increase of adenylate kinase isozyme 1 protein during neuronal differentiation in mouse embryonal carcinoma P19 cells and in rat brain primary cultured cells. J Neurochem 1998; 71: 125-133
51. Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32: 247-258
52. Janssen E, Kuiper J, Hodgson D, Zingman LV, Alekseev AE, Terzic A, Wieringa B. Two structurally distinct and spatially compartmentalized adenylate kinases are expressed from the AK1 gene in mouse brain. Mol Cell Biochem 2004; 256-257: 59-72
53. Belcher SM, Zsarnovszky A, Crawford PA, Hemani H, Spurling L, Kirley TL. Immunolocalization of ecto-nucleoside triphosphate diphosphohydrolase 3 in rat brain: implications for modulation of multiple homeostatic systems including feeding and sleep-wake behaviors. Neuroscience 2006; 137: 1331-1346
54. Appelbaum L, Skariah G, Mourrain P, Mignot E. Comparative expression of p2x receptors and ecto-nucleoside triphosphate diphosphohydrolase 3 in hypocretin and sensory neurons in zebrafish. Brain Res 2007; 1174: 66-75
55. Kast B. The best supporting actors. Nature 2001; 412: 674-676
56. Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, Caciagli F. Trophic effects of purines in neurons and glial cells. Prog Neurobiol 1999; 59: 663-690
57. Ciccarelli R, Ballerini P, Sabatino G, Rathbone MP, D'Onofrio M, Caciagli F, Di Iorio P. Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci 2001; 19: 395-414
58. Zamzow CR, Xiong W, Parkinson FE. Adenosine produced by neurons is metabolized to hypoxanthine by astrocytes. J Neurosci Res 2008; 86: 3447-3455
59. Braun N, Sévigny J, Robson SC, Enjyoji K, Guckelberger O, Hammer K, Di Virgilio F, Zimmermann H. Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain. Eur J Neurosci 2000; 12: 4357-4366